Immunotherapy in GU Cancers Articles | Page 3

IDO Plus PD-1 Inhibitor Combo Sparks Responses in Bladder and Cervical Cancers
The combination of nivolumab and BMS-986205 generated promising response rates without increasing adverse effects in patients with advanced cervical or bladder cancers.
Checkpoint Inhibitors Herald a New Era for Treating Urothelial Cancer
Decades of clinical trials exploring modifications of cytotoxic regimens, including the use of different or more drugs, demonstrated that a therapeutic plateau had been reached with conventional chemotherapeutic agents, highlighting the need for novel approaches in urothelial carcinoma.
Andrea Apolo, MD, discusses the combination of cabozantinib plus nivolumab and ipilimumab, as well as the latest data on avelumab in urothelial carcinoma.
Nivolumab Sustains Survival Benefit in RCC at 3 Years
Nivolumab reduced the risk of death by 26% compared with everolimus in patients with previously treated advanced renal cell carcinoma.
NICE Recommends Frontline Atezolizumab for Advanced Urothelial Cancer
The UK’s National Institute for Health and Care Excellence is recommending the use of atezolizumab for treatment-naïve patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-based therapy.
NICE Rejects Treatments for Bladder and Thyroid Cancer
The UK’s National Institute for Health and Care Excellence has issued guidelines recommending against nivolumab (Opdivo), lenvatinib (Lenvima), and sorafenib (Nexavar).
Novel Immunotherapy Approaches Moving Through RCC Pipeline
Matthew R. Zibelman, MD, discussed the promise of immunotherapy combinations for patients with kidney cancer.
Immunotherapy Agents Leading Advancements in Metastatic Bladder Cancer
The therapeutic landscape is rapidly being altered by clinical trials of immunotherapy for patients with metastatic urothelial carcinoma, but simply changing the way quality of life is monitored could provide dramatic improvements in overall survival.
Exploring the Role of Chemotherapy and Immunotherapy Combos in Urothelial Carcinoma
Andrea Necchi, MD, discusses the current role of immunotherapy and chemotherapy for patients with muscle-invasive bladder cancer.
Pembrolizumab Is Safe and Effective in Cisplatin-Ineligible Advanced Urothelial Carcinoma
As first-line therapy in cisplatin-ineligible advanced urothelial cancer, pembrolizumab (Keytruda) was safe and provided tumor reduction as well as durable responses.
Publication Bottom Border
Border Publication